Shield Therapeutics (AIM: STX)

Last close As at 01/03/2024

GBP0.02

−0.20 (−8.00%)

Market capitalisation

GBP20m

Shield Therapeutics is a commercial-stage pharmaceutical company. Feraccru/Accrufer is approved by the EMA and FDA for iron deficiency. Outside the US, Shield and its commercial partners market Feraccru internationally. Shield signed a US co-commercialisation deal with Nasdaq-listed Viatris in December 2022.

The market for iron deficiency is substantial and Feraccru/Accrufer is a unique oral formulation of iron developed to overcome the side-effect profile of salt-based oral iron therapies and provides an alternative treatment to intravenously administered iron.

Latest Insights

View More

Healthcare | Flash note

Shield Therapeutics — New CFO to support US traction

Healthcare | Flash note

Shield Therapeutics — Delivering what the doctor ordered

Healthcare | Update

Shield Therapeutics — FY23 a key year for business traction

Laboratory

Sector

Healthcare

Equity Analyst

Soo Romanoff

Soo Romanoff

Managing Director - Head of Content, Healthcare

Nidhi Singh

Nidhi Singh

Analyst

Jyoti Prakash

Jyoti Prakash

Analyst, Healthcare

Arron Aatkar

Associate analyst

Key Management

  • Greg Madison

    CEO

  • Santosh Shanbhag

    CFO

Balance Sheet

Forecast net cash (US$m)

6.8

Forecast gearing ratio (%)

N/A

Share Price Performance

Price Performance
% 1M 3M 12M
Actual (63.8) (62.0) (69.7)
Relative (63.7) (63.0) (68.7)
52 week high/low 12.5p/2.3p

Financials

Shield Therapeutics is a UK-headquartered commercial-stage speciality pharmaceutical company focused on the commercialisation of Feraccru/Accrufer (oral ferric maltol), approved by the EMA and FDA to treat iron deficiency in adults, with or without anaemia. Shield launched the product in the US in July 2021 as part of its self-commercialisation strategy. However, it signed a US co-commercialisation deal for Accrufer with Viatris in December 2022. The commercialisation of Feraccru in Europe, Australia and New Zealand is managed by distribution partner Norgine, and it has been licensed to ASK Pharm in China, Korea Pharma in South Korea and KYE Pharma in Canada. Prescription volumes grew 76% q-o-q in Q323 to 27,750 with the company on track to meet its full-year target of ~100–130k US prescriptions. In January 2024, Santosh Shanbhag was appointed as the new CFO.

Y/E Dec Revenue (US$m) EBITDA (US$m) PBT (US$m) EPS (fd) (c) P/E (x) P/CF (x)
2021A N/A N/A N/A N/A N/A N/A
2022A 5.5 (28.7) (31.2) (12.3) N/A N/A
2023E 22.9 (27.9) (29.7) (3.8) N/A N/A
2024E 74.8 (12.0) (15.2) (1.8) N/A N/A

Research

Update

Healthcare

Shield Therapeutics — Accrufer coming to America

Outlook

Healthcare

Shield Therapeutics — Beefing up for the US opportunity

Update

Healthcare

Shield Therapeutics — Close but no cigar

Update

Healthcare

Shield Therapeutics — Next step a US partnering deal

Flash note

Healthcare

Shield Therapeutics — AEGIS-2 update

Update

Healthcare

Shield Therapeutics — 2019 a landmark year

Update

Healthcare

Shield Therapeutics — Feraccru out-licensed in China

edison tv

Healthcare

Bitesize briefing – Shield Therapeutics

Update

Healthcare

Shield Therapeutics — Next step US Feraccru approval

edison tv

Healthcare

Executive interview – Shield Therapeutics

Initiation

Healthcare

Shield Therapeutics — Fortified for growth